dc.contributor.author |
Tornyos, Adrienn |
|
dc.contributor.author |
Aradi, Dániel |
|
dc.contributor.author |
Horváth, Iván |
|
dc.contributor.author |
Kónyi, Attila |
|
dc.contributor.author |
Magyari, Balázs |
|
dc.contributor.author |
Későiné Pintér, Tünde |
|
dc.contributor.author |
Vorobcsuk, András |
|
dc.contributor.author |
Tornyos D |
|
dc.contributor.author |
Komócsi, András |
|
dc.date.accessioned |
2018-08-10T08:27:08Z |
|
dc.date.available |
2018-08-10T08:27:08Z |
|
dc.date.issued |
2017 |
|
dc.identifier |
85037641288 |
|
dc.identifier.citation |
pagination=e0188493, pages 13;
journalVolume=12;
journalIssueNumber=12;
journalTitle=PLOS ONE; |
|
dc.identifier.uri |
http://repo.lib.semmelweis.hu//handle/123456789/5780 |
|
dc.identifier.uri |
doi:10.1371/journal.pone.0188493 |
|
dc.description.abstract |
BACKGROUND: The impact of high platelet reactivity (HPR) on clinical outcomes after elective percutaneous coronary interventions (PCI) with drug-eluting balloons (DEB) due to in-stent restenosis (ISR) is unknown. OBJECTIVE: We sought to evaluate the prognostic importance of HPR together with conventional risk factors in patients treated with DEB. METHODS: Patients treated with DEB due to ISR were enrolled in a single-centre, prospective registry between October 2009 and March 2015. Only patients with recent myocardial infarction (MI) received prasugrel, others were treated with clopidogrel. HPR was defined as an ADP-test >46U with the Multiplate assay and no adjustments were done based on results. The primary endpoint of the study was a composite of cardiovascular mortality, MI, any revascularization or stroke during one-year follow-up. RESULTS: 194 stable angina patients were recruited of whom 90% were treated with clopidogrel. Clinical characteristics and procedural data were available for all patients; while platelet function testing was performed in 152 subjects of whom 32 (21%) had HPR. Patients with HPR had a higher risk for the primary endpoint (HR: 2.45; CI: 1.01-5.92; p = 0.03). The difference was primarily driven by a higher risk for revascularization and MI. According to the multivariate analysis, HPR remained a significant, independent predictor of the primary endpoint (HR: 2.88; CI: 1.02-8.14; p = 0.04), while total DEB length and statin treatment were other independent correlates of the primary outcome. CONCLUSION: HPR was found to be an independent predictor of repeat revascularization and MI among elective patients with ISR undergoing PCI with DEB. |
|
dc.relation.ispartof |
urn:issn:1932-6203 |
|
dc.title |
Clinical outcomes in patients treated for coronary in-stent restenosis with drug-eluting balloons: Impact of high platelet reactivity. |
|
dc.type |
Journal Article |
|
dc.date.updated |
2018-07-13T07:22:03Z |
|
dc.language.rfc3066 |
en |
|
dc.identifier.mtmt |
3302388 |
|
dc.identifier.wos |
000417337800027 |
|
dc.identifier.pubmed |
29216314 |
|
dc.contributor.department |
SE/AOK/K/VAROSMAJOR_SZÍVÉRGYÓGY/Kardiológia Központ - Kardiológiai Tanszék |
|
dc.contributor.institution |
Semmelweis Egyetem |
|